Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James A Charles

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Headache|April 20, 2005
Outpatient continuous intravenous dihydroergotamine for refractory headacheJames A Charles
Headache|September 22, 2007
Headache medicine--a commentJames A Charles
Neurology|May 11, 2011
Trends in American Board of Psychiatry and Neurology specialties and neurologic subspecialtiesJames A Charles
Muscle & Nerve|February 12, 2014
Improving referring physicians' understanding of electromyography reportsJames A Charles
Headache|November 16, 2011
Pathophysiology of chronic migraine and mode of action of preventive medications: a commentJames A Charles
The Journal of Headache and Pain|May 12, 2006
Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safetyJames A Charles
JAMA Neurology|December 22, 2018
Consideration of Costs and Open-label Studies of ErenumabJames A Charles
Headache|January 10, 2014
Roadblock to the only FDA-approved treatment for chronic migraineJames A Charles
Headache|January 9, 2020
In Response to Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and AdolescentsJames A Charles
The Journal of Headache and Pain|May 15, 2007
Early treatment of juvenile migraine reduces disability with disease modification implicationsJames A Charles
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Headache|April 20, 2005
Outpatient continuous intravenous dihydroergotamine for refractory headacheJames A Charles
Headache|September 22, 2007
Headache medicine--a commentJames A Charles
Neurology|May 11, 2011
Trends in American Board of Psychiatry and Neurology specialties and neurologic subspecialtiesJames A Charles
Muscle & Nerve|February 12, 2014
Improving referring physicians' understanding of electromyography reportsJames A Charles
Headache|November 16, 2011
Pathophysiology of chronic migraine and mode of action of preventive medications: a commentJames A Charles
The Journal of Headache and Pain|May 12, 2006
Almotriptan in the acute treatment of migraine in patients 11-17 years old: an open-label pilot study of efficacy and safetyJames A Charles
JAMA Neurology|December 22, 2018
Consideration of Costs and Open-label Studies of ErenumabJames A Charles
Headache|January 10, 2014
Roadblock to the only FDA-approved treatment for chronic migraineJames A Charles
Headache|January 9, 2020
In Response to Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and AdolescentsJames A Charles
The Journal of Headache and Pain|May 15, 2007
Early treatment of juvenile migraine reduces disability with disease modification implicationsJames A Charles
Pageof 3